Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | carnitine palmitoyltransferase 2 | Starlite/ChEMBL | No references |
Homo sapiens | carnitine palmitoyltransferase 1A (liver) | Starlite/ChEMBL | No references |
Rattus norvegicus | Carnitine palmitoyltransferase 1A | Starlite/ChEMBL | No references |
Homo sapiens | carnitine palmitoyltransferase 1B (muscle) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | carnitine O-acetyltransferase, putative | carnitine palmitoyltransferase 2 | 658 aa | 629 aa | 30.7 % |
Candida albicans | similar to S. cerevisiae YAT2 putative carnitine O-acetyltransferase | Carnitine palmitoyltransferase 1A | 773 aa | 645 aa | 25.6 % |
Onchocerca volvulus | Carnitine palmitoyltransferase 1A | 773 aa | 758 aa | 43.8 % | |
Trypanosoma cruzi | choline/carnitine O-acetyltransferase, putative | carnitine palmitoyltransferase 1B (muscle) | 738 aa | 617 aa | 28.0 % |
Candida albicans | similar to S. cerevisiae YAT2 putative carnitine O-acetyltransferase | Carnitine palmitoyltransferase 1A | 773 aa | 645 aa | 25.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.0406 | 0.4222 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0754 | 0.0056 |
Brugia malayi | Hypothetical zinc metalloproteinase T16A9.4 | 0.0212 | 0.1482 | 0.0275 |
Loa Loa (eye worm) | hypothetical protein | 0.0212 | 0.1482 | 0.084 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0754 | 0.0056 |
Echinococcus multilocularis | endothelin converting enzyme 1 | 0.0212 | 0.1482 | 0.0807 |
Loa Loa (eye worm) | choline/Carnitine O-acyltransferase | 0.0195 | 0.1242 | 0.0581 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0754 | 0.0056 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0406 | 0.4222 | 1 |
Toxoplasma gondii | peptidase family M13 protein | 0.0212 | 0.1482 | 0.5 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0195 | 0.1242 | 0.5 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0406 | 0.4222 | 1 |
Mycobacterium tuberculosis | Probable zinc metalloprotease Zmp1 | 0.0212 | 0.1482 | 0.5 |
Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.0406 | 0.4222 | 1 |
Mycobacterium leprae | probable zinc metalloprotease | 0.0212 | 0.1482 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0754 | 0.0056 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0754 | 0.0056 |
Loa Loa (eye worm) | hypothetical protein | 0.0814 | 1 | 1 |
Mycobacterium ulcerans | zinc metalloprotease | 0.0212 | 0.1482 | 0.5 |
Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.0406 | 0.4222 | 1 |
Schistosoma mansoni | family M13 unassigned peptidase (M13 family) | 0.0212 | 0.1482 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0.0754 | 0.0056 |
Loa Loa (eye worm) | hypothetical protein | 0.0212 | 0.1482 | 0.084 |
Brugia malayi | Peptidase family M13 containing protein | 0.0212 | 0.1482 | 0.0275 |
Echinococcus granulosus | endothelin converting enzyme 1 | 0.0212 | 0.1482 | 0.0807 |
Loa Loa (eye worm) | hypothetical protein | 0.0212 | 0.1482 | 0.084 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.0695 uM | SUPPLEMENTARY | SUPPLEMENTARY. | No reference |
IC50 (binding) | = 0.1021 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 1, liver isoform | ChEMBL. | No reference |
IC50 (binding) | = 4.0733 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 1, muscle isoform | ChEMBL. | No reference |
IC50 (binding) | = 11.4517 uM | SUPPLEMENTARY | SUPPLEMENTARY. | No reference |
IC50 (binding) | = 22.4997 uM | SUPPLEMENTARY: Inhibition of Carnitine palmitoyltransferase 2 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.